Report examines whether early recovery of circulating lymphocytes after steroid start predicts cardiovascular events and death in patients with immunotherapy myocarditis.
Key Takeaways
- Immune checkpoint inhibitors (ICIs) have profoundly improved outcomes across a wide range of cancer therapy
- Expanding usage of ICIs can cause a variety of immune-related adverse events (irAEs)
- ICIAM is notable for early onset of 21–34 days after ICIs-treatment initiation